为HPV疫苗接种女性调整宫颈癌筛查:分层指南的价值
该研究用挪威HPV诱导宫颈癌数学模型,评估74种筛查策略在接种二价/四价或九价HPV疫苗女性中的长期健康收益、资源与成本。
要点
- 九价疫苗接种女性最具成本效果的策略为终生一次HPV检测。
- 二价/四价疫苗接种女性最宜终生两次HPV检测。
核心结论
- HPV疫苗接种女性需更低强度筛查策略以保持成本效果。
- 即使投入较大成本识别个体接种状态并分层指南,筛查仍可具成本效果。
研究设计与样本
- 基于挪威HPV诱导宫颈癌的数学模型,预测74种筛查策略的长期健康收益、资源与成本。
- 策略按筛查检测、开始年龄和频率区分,并分别针对二价/四价与九价疫苗接种女性评估。
- 采用成本效果框架(增量成本效果比与净货币收益)及挪威常用支付意愿阈值每获得质量调整生命年75000欧元。
主要发现
- 九价疫苗接种女性最具成本效果的策略为终生一次HPV检测。
- 二价/四价疫苗接种女性最具成本效果的策略为终生两次HPV检测。
- 按接种状态分层指南的价值为二价/四价接种女性每人599欧元、九价接种女性每人725欧元。
关键数值与推荐
- 成本效果判断采用挪威常用支付意愿阈值每质量调整生命年75000欧元。
- 九价疫苗接种女性推荐终生一次HPV检测,二价/四价疫苗接种女性推荐终生两次HPV检测。
- 分层指南每人价值:二价/四价599欧元,九价725欧元。
临床怎么用
- 对HPV疫苗接种女性可考虑降低宫颈癌筛查强度,如减少终生HPV检测次数。
- 可投入资源识别个体HPV疫苗接种状态,并据此分层制定筛查指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several countries have implemented vaccination against human papillomavirus (HPV) for adolescent girls and must decide whether and how to adapt cervical cancer (CC) screening for these low-risk women. We aimed to identify the optimal screening strategies for women vaccinated against HPV infections and quantify the amount that could be spent to identify vaccination status among women and stratify CC screening guidelines accordingly. METHODS: We used a mathematical model reflecting HPV-induced CC in Norway to project the long-term health benefits, resources and costs associated with 74 candidate-screening strategies that varied by screening test, start age and frequency. Strategies were considered separately for women vaccinated with the bivalent/quadrivalent (2/4vHPV) and nonavalent (9vHPV) vaccines. We used a cost-effectiveness framework (i.e. incremental cost-effectiveness ratios and net monetary benefit) and a commonly-cited Norwegian willingness-to-pay threshold of €75,000 per quality-adjusted life-year gained. RESULTS: The most cost-effective screening strategy for 9vHPV- and 2/4vHPV-vaccinated women involved HPV testing once and twice per lifetime, respectively. The value of stratifying guidelines by vaccination status was €599 (2/4vHPV) and €725 (9vHPV) per vaccinated woman. Consequently, for the first birth cohort of ∼22,000 women who were vaccinated in adolescence in Norway, between €10.5-13.2 million over their lifetime could be spent on identifying individual vaccination status and stratify screening while remaining cost-effective. CONCLUSION: Less intensive strategies are required for CC screening to remain cost-effective in HPV-vaccinated women. Moreover, screening can remain cost-effective even if large investments are made to identify individual vaccination status and stratify screening guidelines accordingly.
引用
- Pedersen K, Burger EA, Nygård M, et al. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines. Eur J Cancer. 2018. PMID: 29335156. doi:10.1016/j.ejca.2017.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。